D.A. Davidson & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.5M Sell
212,815
-6,899
-3% -$1.06M 0.2% 85
2025
Q4
$30.3M Sell
219,714
-4,833
-2% -$633K 0.19% 88
2025
Q3
$28.8M Sell
224,547
-106,074
-32% -$12.9M 0.18% 97
2025
Q2
$40M Sell
330,621
-68,710
-17% -$7.74M 0.28% 66
2025
Q1
$44.5M Sell
399,331
-65,251
-14% -$6.95M 0.36% 56
2024
Q4
$45.2M Sell
464,582
-22,558
-5% -$2.41M 0.37% 48
2024
Q3
$56M Sell
487,140
-4,942
-1% -$561K 0.46% 44
2024
Q2
$52.4M Sell
492,082
-1,220
-0.2% -$122K 0.46% 43
2024
Q1
$47.7M Buy
493,302
+6,225
+1% +$638K 0.43% 44
2023
Q4
$49.2M Sell
487,077
-10,100
-2% -$975K 0.48% 43
2023
Q3
$50.6M Buy
497,177
+669
+0.1% +$67.9K 0.55% 37
2023
Q2
$50.1M Sell
496,508
-20,901
-4% -$2.09M 0.53% 37
2023
Q1
$47.6M Buy
517,409
+29,725
+6% +$2.6M 0.54% 38
2022
Q4
$44.2M Buy
487,684
+3,819
+0.8% +$322K 0.52% 42
2022
Q3
$36.8M Buy
483,865
+10,043
+2% +$832K 0.48% 46
2022
Q2
$40.1M Buy
473,822
+4,237
+0.9% +$372K 0.5% 39
2022
Q1
$41.2M Buy
469,585
+20,123
+4% +$1.74M 0.45% 47
2021
Q4
$39.3M Buy
449,462
+15,638
+4% +$1.3M 0.42% 52
2021
Q3
$35.5M Buy
433,824
+3,455
+0.8% +$311K 0.41% 47
2021
Q2
$39.3M Buy
430,369
+17,893
+4% +$1.59M 0.46% 44
2021
Q1
$35.3M Buy
412,476
+60,072
+17% +$5.39M 0.45% 45
2020
Q4
$33.3M Buy
352,404
+12,657
+4% +$1.11M 0.51% 39
2020
Q3
$29.5M Buy
339,747
+12,656
+4% +$1.1M 0.51% 40
2020
Q2
$28.6M Sell
327,091
-54,306
-14% -$4.69M 0.53% 38
2020
Q1
$31.4M Buy
381,397
+25,513
+7% +$2.28M 0.61% 35
2019
Q4
$33.7M Buy
355,884
+16,123
+5% +$1.45M 0.54% 41
2019
Q3
$29.5M Buy
339,761
+10,687
+3% +$960K 0.53% 42
2019
Q2
$30M Sell
329,074
-208,665
-39% -$17.7M 0.56% 40
2019
Q1
$46.2M Buy
537,739
+9,657
+2% +$775K 0.79% 29
2018
Q4
$40.6M Buy
528,082
+13,020
+3% +$1.01M 0.79% 30
2018
Q3
$39.8M Buy
515,062
+23,966
+5% +$1.77M 0.71% 30
2018
Q2
$33.2M Buy
491,096
+11,087
+2% +$765K 0.65% 31
2018
Q1
$34.8M Buy
480,009
+7,325
+2% +$558K 0.72% 28
2017
Q4
$35.6M Sell
472,684
-103,316
-18% -$7.8M 0.75% 30
2017
Q3
$44.3M Buy
576,000
+3,769
+0.7% +$285K 0.87% 16
2017
Q2
$42.8M Buy
572,231
+61,460
+12% +$4.36M 0.97% 18
2017
Q1
$34M Buy
510,771
+55,374
+12% +$3.69M 0.82% 22
2016
Q4
$29.7M Buy
455,397
+27,516
+6% +$1.78M 0.67% 27
2016
Q3
$30.3M Buy
427,881
+47,238
+12% +$3.44M 0.75% 22
2016
Q2
$28.1M Buy
380,643
+38,589
+11% +$2.67M 0.83% 18
2016
Q1
$22.2M Buy
342,054
+20,682
+6% +$1.41M 0.69% 22
2015
Q4
$24.8M Buy
321,372
+17,505
+6% +$1.39M 0.81% 21
2015
Q3
$25M Buy
303,867
+3,700
+1% +$329K 0.88% 17
2015
Q2
$26.4M Buy
300,167
+1,423
+0.5% +$131K 0.87% 15
2015
Q1
$26.4M Sell
298,744
-9,269
-3% -$822K 0.87% 17
2014
Q4
$25.6M Buy
308,013
+2,757
+0.9% +$229K 0.84% 19
2014
Q3
$25.7M Buy
305,256
+9,516
+3% +$770K 0.87% 16
2014
Q2
$24M Buy
295,740
+26,037
+10% +$2.05M 0.81% 19
2014
Q1
$20.5M Buy
269,703
+20,679
+8% +$1.51M 0.73% 23
2013
Q4
$17.9M Buy
249,024
+9,979
+4% +$694K 0.67% 27
2013
Q3
$16.4M Buy
239,045
+15,941
+7% +$1.05M 0.74% 21
2013
Q2
$14.1M Buy
+223,104
New +$14.5M 0.68% 24

Other funds holding NVS

D.A. Davidson & Co's NVS Position: Q1 2026 in Review

D.A. Davidson & Co reduced its Novartis (NVS) stake by 3.1% in Q1 2026, selling an estimated $1.06M and leaving 212,815 shares worth $32.5M. The position accounts for 0.2% of the portfolio, ranked #85.

D.A. Davidson & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $56M in Q3 2024. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • D.A. Davidson & Co held 212,815 shares of Novartis worth $32.5M as of Q1 2026.
  • D.A. Davidson & Co sold 6,899 Novartis shares in Q1 2026, an estimated $1.06M.
  • Novartis made up 0.2% of D.A. Davidson & Co's portfolio in Q1 2026, its #85 holding.
  • D.A. Davidson & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • D.A. Davidson & Co's Novartis position peaked at $56M in Q3 2024.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on D.A. Davidson & Co's 13F filing for Q1 2026, filed 5 May 2026.